FINWIRES · TerminalLIVE
FINWIRES

Samsung Pharmaceutical Voluntarily Withdraws Phase 3 Clinical Trial Application for GV 1001

By

Samsung Pharmaceutical (KRX:001360) has voluntarily withdrawn its application for a changed Phase 3 clinical trial plan for GV 1001, a treatment for Progressive Supranuclear Palsy-Richardson's Syndrome (PSP-RS).

The application was originally submitted to South Korea's Ministry of Food and Drug Safety (MFDS) on July 1, according to a filing on Wednesday.

The withdrawal follows an MFDS request for supplementary data during the review process, with the company determining it would be more appropriate to prepare a comprehensive response and reapply.

The company stated it plans to supplement the relevant materials promptly and reapply for Investigational New Drug or IND approval.

What else is happening in Asia?

Asia

Shenzhen Megmeet Electrical Buys Out 46.3% Stake in Subsidiary

Shenzhen Megmeet Electrical (SHE:002851) will purchase the remaining 46.3% stake it does not own in subsidiary Shenzhen Megmeet Welding Technology for 663.6 million yuan, according to a Wednesday filing with the Shenzhen bourse.Following the sale of the stakes of 46 shareholders, the listed company will fully own the subsidiary.

SHE:002851
Asia

Zhejiang Wanliyang Appoints CFO

Zhejiang Wanliyang (SHE:002434) appointed Shi Yuqiong as chief financial officer after Zhang Leigang resigned from the top financial role due to a change in work responsibilities, according to a Shenzhen bourse filing on Wednesday.Shi's appointment came into effect on Tuesday. The term runs through the end of the current board's tenure.Qian Shouguang was also appointed head of the internal audit department after the previous department head resigned, the filing said.Shares of the Chinese auto transmission systems manufacturer fell over 2% in recent trade.

SHE:002434
Asia

Carimin Petroleum Raises Stake in Sealink International to 25.3%

Carimin Petroleum (KLSE:CARIMIN) acquired a 5.8% stake in Sealink International (KLSE:SEALINK) for 9.9 million ringgit in cash, according to a Tuesday filing with Bursa Malaysia.The acquisition involved 29.1 million shares bought at 0.34 ringgit each, between Sept. 18 and Sept. 22.Following the acquisition, Carimin's stake in Sealink rose to 25.3% from 19.5%, making Sealink an associate company.Carimin Petroleum said the acquisition was part of its ongoing investment strategy.The deal was funded through internally generated funds and does not require shareholder or regulatory approval, the filing said.

KLSE:CARIMINKLSE:SEALINK